Intangible Assets (Tables)

12 Months Ended

Oct. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

(In millions)	CooperVision		CooperSurgical		Total
Balance at October 31, 2023	$	1,747.6	$	1,876.9	$	3,624.5
Net additions	—		157.8		157.8
Foreign currency translation adjustment	50.2		5.9		56.1
Balance at October 31, 2024	$	1,797.8	$	2,040.6	$	3,838.4

Schedule of Finite-Lived Intangible Assets

Other Intangible Assets

	October 31, 2024				October 31, 2023
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted-average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	204.2	$	90.6	$	208.9	$	81.1	15
Composite intangible assets (1)	1,101.6		496.8		1,061.9		424.8		15
Technology	706.4		384.3		494.5		335.4		11
Customer relationships	1,130.5		402.5		1,099.2		345.8		19
License and distribution rights and other	47.9		27.2		51.6		28.0		11
	3,190.6		$	1,401.4	2,916.1		$	1,215.1	16
Less: accumulated amortization and translation	1,401.4				1,215.1
Intangible assets with definite lives, net	$	1,789.2			$	1,701.0
Intangible assets with indefinite lives, net (2)	1.8				9.3
Total other intangibles, net	$	1,791.0			$	1,710.3

(1) Composite intangible assets primarily consist of technology, trade name, New Drug Application approval and physician relationships. The components are not reflected separately or within the corresponding categories because they are inextricably linked.

(2) Intangible assets with indefinite lives include technology and trademarks.

Schedule of Indefinite-Lived Intangible Assets

Other Intangible Assets

	October 31, 2024				October 31, 2023
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted-average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	204.2	$	90.6	$	208.9	$	81.1	15
Composite intangible assets (1)	1,101.6		496.8		1,061.9		424.8		15
Technology	706.4		384.3		494.5		335.4		11
Customer relationships	1,130.5		402.5		1,099.2		345.8		19
License and distribution rights and other	47.9		27.2		51.6		28.0		11
	3,190.6		$	1,401.4	2,916.1		$	1,215.1	16
Less: accumulated amortization and translation	1,401.4				1,215.1
Intangible assets with definite lives, net	$	1,789.2			$	1,701.0
Intangible assets with indefinite lives, net (2)	1.8				9.3
Total other intangibles, net	$	1,791.0			$	1,710.3

(1) Composite intangible assets primarily consist of technology, trade name, New Drug Application approval and physician relationships. The components are not reflected separately or within the corresponding categories because they are inextricably linked.

(2) Intangible assets with indefinite lives include technology and trademarks.

Remaining Amortization Expenses for Intangible Assets with Definite Lives

As of October 31, 2024, the estimate of future amortization expenses for intangible assets with definite lives is as follows:

Fiscal years:	(In millions)
2025	$	197.7
2026	190.1
2027	175.8
2028	171.3
2029	167.2
Thereafter	887.1
Total remaining amortization for intangible assets with definite lives	$	1,789.2